← Leaderboards
Linda M Liau
University Of California Los Angeles
$8,990,878
Attributed
$10,102,959
Total exposure
23
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,039,691 · 24
By mechanism
P50$22,767,896 · 9
R01$5,050,874 · 3
R25$1,159,321 · 1
R21$697,518 · 1
K08$218,824 · 1
M01$145,258 · 9
Top collaborators
- Carol A Kruse7 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Antoni Ribas$28,929,216
- Ichiro Nakano$7,010,147
- Robert M Prins$8,963,397
- James S. Economou$9,911,213
- Scott G Kitchen$17,099,191
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelBrain NeoplasmsProgramsResearch Project GrantsTranslational ResearchMalignant Neoplasm Of BrainResourcesInnovationFundingCareerUnited States National Institutes Of HealthInstitutionClinical ResearchBrainDiagnosisGliomaMonitorScientistGrantSuccessCareer DevelopmentCommunitiesResearch SupportFostering
Grant awards (79)
UCLA SPORE in Brain Cancer$2,161,493
P50 · FY2025 · CA · contact PI
Administrative Core$196,512
P50 · FY2025 · CA · contact PI
Career Enhancement Program$89,424
P50 · FY2025 · CA · contact PI
UCLA SPORE in Brain Cancer$86,121
P50 · FY2025 · CA · contact PI
Administrative Core$8,613
P50 · FY2025 · CA · contact PI
Career Enhancement Program$8,612
P50 · FY2025 · CA · contact PI
UCLA SPORE in Brain Cancer$2,112,473
P50 · FY2024 · CA · contact PI
Administrative Core$201,857
P50 · FY2024 · CA · contact PI
Career Enhancement Program$91,857
P50 · FY2024 · CA · contact PI
Investigating Mechanisms of Adaptive Immune Resistance to Combination Immunotherapy within the Glioblastoma Microenvironment$86,121
P50 · FY2024 · CA · contact PI
UCLA SPORE in Brain Cancer$2,046,404
P50 · FY2023 · CA · contact PI
Novel mouse models using MADR-GESTALT technology to accelerate glioma research$235,632
P50 · FY2023 · CA · contact PI
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer$235,632
P50 · FY2023 · CA · contact PI
Administrative Core$184,583
P50 · FY2023 · CA · contact PI
Career Enhancement Program$83,994
P50 · FY2023 · CA · contact PI
UCLA SPORE in Brain Cancer$2,046,459
P50 · FY2022 · CA · contact PI
Administrative Core$181,574
P50 · FY2022 · CA · contact PI
Career Enhancement Program$82,628
P50 · FY2022 · CA · contact PI
UCLA SPORE in Brain Cancer$2,139,000
P50 · FY2021 · CA · contact PI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma$345,823
P50 · FY2021 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$226,926
R25 · FY2021 · NS · contact PI
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer$214,029
P50 · FY2021 · CA · contact PI
Novel mouse models using MADR-GESTALT technology to accelerate glioma research$214,029
P50 · FY2021 · CA · contact PI
Administrative Core$108,036
P50 · FY2021 · CA · contact PI
UCLA SPORE in Brain Cancer$2,185,000
P50 · FY2020 · CA · contact PI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma$353,385
P50 · FY2020 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$139,874
R25 · FY2020 · NS · contact PI
Administrative Core$110,399
P50 · FY2020 · CA · contact PI
UCLA SPORE in Brain Cancer$2,139,000
P50 · FY2019 · CA · contact PI
Administrative Core$108,033
P50 · FY2019 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$73,729
R25 · FY2019 · NS · contact PI
UCLA SPORE in Brain Cancer$2,300,000
P50 · FY2018 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$128,734
R25 · FY2018 · NS · contact PI
Administrative Core$116,202
P50 · FY2018 · CA · contact PI
UCLA SPORE in Brain Cancer$2,185,000
P50 · FY2017 · CA · contact PI
Administrative Core$109,971
P50 · FY2017 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$66,307
R25 · FY2017 · NS · contact PI
UCLA Neurosurgery Research Training and Education Program$65,708
R25 · FY2016 · NS · contact PI
UCLA Neurosurgery Research Training and Education Program$122,995
R25 · FY2015 · NS · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$212,019
R01 · FY2014 · CA · contact PI
UCLA Neurosurgery Research Training and Education Program$66,828
R25 · FY2014 · NS · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$14,664
R01 · FY2014 · CA
UCLA Neurosurgery Research Training and Education Program$2,160
R25 · FY2014 · NS · contact PI
UCLA Neurosurgery Research Training and Education Program$1
R25 · FY2014 · NS · contact PI
UCLA Neurosurgery Research Training and Education Program$162,225
R25 · FY2013 · NS · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$61,181
R01 · FY2013 · CA
UCLA Neurosurgery Research Training and Education Program$4,860
R25 · FY2013 · NS · contact PI
UCLA Neurosurgery Research Training and Education Program$1
R25 · FY2013 · NS · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$1
R01 · FY2013 · CA
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$685,920
R01 · FY2012 · CA
UCLA Neurosurgery Research Training and Education Program$98,973
R25 · FY2012 · NS · contact PI
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$49,970
R01 · FY2012 · CA
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$690,480
R01 · FY2011 · CA
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas$721,946
R01 · FY2010 · CA
PACAP Modulation of Shh Signaling in Medulloblastoma$266,286
R01 · FY2010 · CA · contact PI
Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma$253,548
R01 · FY2010 · CA · contact PI
CLINICAL TRIAL: PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED$23,732
M01 · FY2010 · RR · contact PI
A PHASE I STUDY TO EVALUATE THE SAFETY, IMMUNE RESPONSIVENESS, AND SURVIVAL OF G$19,118
M01 · FY2010 · RR · contact PI
PACAP Modulation of Shh Signaling in Medulloblastoma$266,286
R01 · FY2009 · CA · contact PI
Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma$253,548
R01 · FY2009 · CA · contact PI
CLINICAL TRIAL: PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED$16,809
M01 · FY2009 · RR · contact PI
A PHASE I STUDY TO EVALUATE THE SAFETY, IMMUNE RESPONSIVENESS, AND SURVIVAL OF G$3,448
M01 · FY2009 · RR · contact PI
PACAP Modulation of Shh Signaling in Medulloblastoma$266,286
R01 · FY2008 · CA · contact PI
Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma$253,548
R01 · FY2008 · CA · contact PI
CLINICAL TRIAL: PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED$12,120
M01 · FY2008 · RR · contact PI
PACAP Modulation of Shh Signaling in Medulloblastoma$266,286
R01 · FY2007 · CA · contact PI
Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma$253,548
R01 · FY2007 · CA · contact PI
PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED DENDRITIC CEL$25,758
M01 · FY2007 · RR · contact PI
PACAP Modulation of Shh Signaling in Medulloblastoma$274,238
R01 · FY2006 · CA · contact PI
Dendritic Cell-based Vaccine Targeting MAA in Malignant Glioma$261,119
R01 · FY2006 · CA · contact PI
PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED DENDRITIC CEL$22,021
M01 · FY2006 · RR · contact PI
PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED DENDRITIC CEL$17,613
M01 · FY2005 · RR
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cel...$4,366
M01 · FY2004 · RR
Phase I Dose Escalation Study of Autologous Antigen-Pulsed Dendritic Cell Imm...$273
M01 · FY2004 · RR
Phase I Study of Dendritic Cell Immunotherapy$320,250
R21 · FY2002 · CA
Phase I Study of Dendritic Cell Immunotherapy$55,968
R21 · FY2002 · CA
Phase I Study of Dendritic Cell Immunotherapy$321,300
R21 · FY2001 · CA
GLIOMA SPECIFIC GENES IN BRAIN TUMOR IMMUNOTHERAPY$111,558
K08 · FY2001 · CA
GLIOMA SPECIFIC GENES IN BRAIN TUMOR IMMUNOTHERAPY$107,266
K08 · FY2000 · CA